File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Somatic Mutations of PIK3R1 Promote Gliomagenesis

TitleSomatic Mutations of PIK3R1 Promote Gliomagenesis
Authors
Issue Date2012
Citation
PLoS ONE, 2012, v. 7, n. 11 How to Cite?
AbstractThe phosphoinositide 3-kinase (PI3K) pathway is targeted for frequent alteration in glioblastoma (GBM) and is one of the core GBM pathways defined by The Cancer Genome Atlas. Somatic mutations of PIK3R1 are observed in multiple tumor types, but the tumorigenic activity of these mutations has not been demonstrated in GBM. We show here that somatic mutations in the iSH2 domain of PIK3R1 act as oncogenic driver events. Specifically, introduction of a subset of the mutations identified in human GBM, in the nSH2 and iSH2 domains, increases signaling through the PI3K pathway and promotes tumorigenesis of primary normal human astrocytes in an orthotopic xenograft model. Furthermore, we show that cells that are dependent on mutant P85α-mediated PI3K signaling exhibit increased sensitivity to a small molecule inhibitor of AKT. Together, these results suggest that GBM patients whose tumors carry mutant PIK3R1 alleles may benefit from treatment with inhibitors of AKT. © 2012 Quayle et al.
Persistent Identifierhttp://hdl.handle.net/10722/225041

 

DC FieldValueLanguage
dc.contributor.authorQuayle, Steven N.-
dc.contributor.authorLee, Jennifer Y.-
dc.contributor.authorCheung, Lydia W T-
dc.contributor.authorDing, Li-
dc.contributor.authorWiedemeyer, Ruprecht-
dc.contributor.authorDewan, Robert W.-
dc.contributor.authorHuang-Hobbs, Emmet-
dc.contributor.authorZhuang, Li-
dc.contributor.authorWilson, Richard K.-
dc.contributor.authorLigon, Keith L.-
dc.contributor.authorMills, Gordon B.-
dc.contributor.authorCantley, Lewis C.-
dc.contributor.authorChin, Lynda-
dc.date.accessioned2016-04-18T11:16:36Z-
dc.date.available2016-04-18T11:16:36Z-
dc.date.issued2012-
dc.identifier.citationPLoS ONE, 2012, v. 7, n. 11-
dc.identifier.urihttp://hdl.handle.net/10722/225041-
dc.description.abstractThe phosphoinositide 3-kinase (PI3K) pathway is targeted for frequent alteration in glioblastoma (GBM) and is one of the core GBM pathways defined by The Cancer Genome Atlas. Somatic mutations of PIK3R1 are observed in multiple tumor types, but the tumorigenic activity of these mutations has not been demonstrated in GBM. We show here that somatic mutations in the iSH2 domain of PIK3R1 act as oncogenic driver events. Specifically, introduction of a subset of the mutations identified in human GBM, in the nSH2 and iSH2 domains, increases signaling through the PI3K pathway and promotes tumorigenesis of primary normal human astrocytes in an orthotopic xenograft model. Furthermore, we show that cells that are dependent on mutant P85α-mediated PI3K signaling exhibit increased sensitivity to a small molecule inhibitor of AKT. Together, these results suggest that GBM patients whose tumors carry mutant PIK3R1 alleles may benefit from treatment with inhibitors of AKT. © 2012 Quayle et al.-
dc.languageeng-
dc.relation.ispartofPLoS ONE-
dc.titleSomatic Mutations of PIK3R1 Promote Gliomagenesis-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1371/journal.pone.0049466-
dc.identifier.pmid23166678-
dc.identifier.scopuseid_2-s2.0-84869118340-
dc.identifier.volume7-
dc.identifier.issue11-
dc.identifier.eissn1932-6203-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats